Objectives: We realized a longitudinal open-label study to determine if increasing intervals between etanercept (ETN) administration could be effective in maintaining remission with a stable dose in a patient population affected by psoriatic arthritis (PsA) who had achieved sustained remission with ETN 25 mg biweekly.
tanercept (ETN) has been shown to be effective in patients with psoriatic arthritis (PsA) in many randomized placebo-controlled trials, [1] [2] [3] [4] as well as in observational studies representing routine clinical practice. [5] [6] [7] There is a lack of consensus on the attitude to adopt in presence of sustained clinical remission under biological therapy. Some observational studies have suggested an intermittent therapeutic strategy, [8] [9] [10] whereas others suggest the possibility of identifying the lowest effective dose of biological agents for a considerable percentage of PsA patients, either by using lower doses or by increasing intervals between dose administrations. [11] [12] [13] [14] [15] The latter mentioned practice has been recently implemented empirically in the rheumatology, especially to achieve cost-effectiveness.
We realized a longitudinal open-label study to determine if increasing intervals between ETN administration could be effective in maintaining remission with a stable dose in a patient population affected by PsA who had achieved sustained remission with ETN 25 mg biweekly.
MATERIALS AND METHODS
Fifty-four PsA patients, classified according to the CASPAR (Classification Criteria for Psoriatic Arthritis) criteria, 16 were recruited between September 2012 and June 2015 at the Rheumatology Unit of Azienda Ospedaliera Universitaria Senese.
Patients included had a disease duration of more than 1 year and age older than 18 years but younger than 65 years and an active disease, defined as at least 3 tender joints and at least 3 swollen joints for the patients with peripheral arthritis and as Exclusion criteria were the presence of significant comorbidities, including active infection, cardiac failure (New York Heart Association class III/IV), malignancy, elevated liver enzymes, a serum creatinine level greater than 1.20 mg/L, alcohol and/or drug abuse, pregnancy, and demyelinating diseases. Patients who tested positive for latent tuberculosis with evidence of latent viral hepatitis were excluded from the study. Signed informed consent was obtained from each patient.
Included patients discontinued the synthetic DMARDs, while they kept assuming NSAIDs and CS and self-administered 25 mg of ETN (Wyatt) biweekly subcutaneously: at our institute, in patients with PsA, we initially use ETN with a regimen of 25 mg biweekly in agreement with Mease et al. [1] [2] [3] Patients were followed up during 1 year and evaluated at baseline, after 3 months, and every 1 month thereafter; at each visit, all patients underwent routine laboratory tests, joint examination, and general assessment. Moreover, the following measures were recorded:
1. BASDAI using 1-to 10-point score for each item; 2. patient's assessment of disease activity using 1-to 10-point score; 3. patient's assessment of pain using visual analog scale (VAS) 1-to 10-point score; 4. entheseal tenderness/pain-scored in 15 body sites (0 = absent, 1 = present) using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score; 5. a swollen joint count assessing 64 joints; and 6. dactylitis-assessed in 20 digits of the hands and feet on a scale of 0 to 3 (0 = no dactylitis, 3 = severe dactylitis).
Clinical sustained remission was defined as a period of at least 2 consecutive clinical examinations with absence of actively inflamed joints (value of <2 on a 1-to 10-point scale in each of 4 Assessment of Spondyloarthritis International Society domains, BASDAI score of less than 2, and absence of peripheral arthritis, enthesitis, and dactylitis), absence of inflammatory extra-articular and extracutaneous manifestations, and normalization of acutephase reactants (C-reactive protein [CRP]), without taking any additional drugs including NSAIDs and CS). Psoriasis severity was assessed based on the Psoriasis Area and Severity Index (PASI) score; a 75% improvement in PASI (PASI-75) is used as a primary end point and indicates a highly effective outcome. At each examination, any adverse effect, either reported or observed, was recorded.
According to the protocol, patients, who were in clinical sustained remission with biweekly ETN 25 mg at weeks 12 and 16, were switched into a weekly regimen. If clinical remission, despite the increase in drug-free interval, persisted at weeks 24 and 28, patients were switched into an every-other-week regimen, Those who maintained clinical remission at weeks 36 and 40 kept the same administration schedule for the entire duration of the study. On the contrary, those who relapsed with the appearance of actively inflamed joints and/or inflammatory extra-articular and extra-cutaneous manifestations and/or increase in acute-phase reactants, the therapeutic schedule went back to the previous effective one. In case aggravated cutaneous manifestations were not tolerated by the patient, we went back to the previous efficient therapeutic schema.
The primary end point is the proportion of patients in sustained clinical remission at week 48 with weekly ETN 25 mg therapy and with every-other-week ETN 25-mg therapy. In addition, the correlation between the incidence of adverse effects and the pattern of drug administration and the presence of markers able to predict the possibility of disease remission even with reduced dose of ETN were evaluated.
Statistical Analysis
The results are expressed as the mean ± SD. The differences between the parameters examined and the various incidences of the adverse effects among populations were calculated using the Student t test for paired data. Pearson test was also applied to calculate the coefficient of linear correlation between the basal parameters and the size of the therapeutic effect.
RESULTS
Baseline characteristics of the study population are shown in the Table. At Patients in sustained clinical remission at 16 weeks were switched into a weekly regimen. Baseline characteristics of patients who initiated the tapering are shown in the Table. In this group, 2 patients with peripheral polyarthritis showed a reactivation of the disease between the 20th and 24th weeks and were thus brought back to a biweekly regimen, and 1 patient with peripheral oligoarthritis interrupted treatment because of bronchopulmonary complication. The rest of the group, 26 patients (89%), were still in remission: 13 of them, however, showed a significant increase in PASI. Two patients, 1 patient with peripheral oligoarthritis and 1 patient with axial pattern, showing a marked exacerbation of cutaneous manifestations were brought back to a biweekly regimen (Fig) .
The 24 patients (83%) who were in clinical remission and with a satisfactory reduction of skin manifestations at 28 weeks were switched into an every-other-week regimen. The 4 patients who switched from weekly to biweekly regimen showed a remission of arthritic manifestations and a reduction in PASI compared with what they initially obtained; these patients will continue until the end of the study taking ETN with biweekly regimen.
At week 32, among the 24 every-other-week-regimen patients, 4 patients (2 with peripheral polyarthritis, 1 with peripheral oligoarthritis, and 1 with axial pattern) showed a disease activity reactivation, and the other 4 patients showed a marked exacerbation of cutaneous manifestations; these 8 patients were brought back to a weekly regimen. On the contrary the other 16 patients continued with an every-other-week regimen showing a sustained with peripheral oligoarthritis has discontinued therapy because of adverse effects (herpes zoster). Of the 8 patients who were brought back to a weekly regimen, 6 still showed a remission of arthritic manifestations and a reduction in PASI comparable to that initially obtained at 36 weeks and continued until the end of the study taking ETN with weekly regimen. The other 2 patients, both with a peripheral polyarthritis, were brought back to a biweekly regimen because of the persistence of arthritis manifestations at week 36.
In conclusion, at the end of the study 27 patients (93%) were still in remission, 6 (21%) with a biweekly regimen, 6 (21%) with a weekly regimen, and 15(51%) with an every-other-week regimen. A higher number of subjects presenting peripheral oligoarthritis (44%, 7/16 patients) and axial pattern (42%, 5/12) than those with peripheral polyarthritis (11%, 3/26 patients) achieved clinical remission among those with an every-other-week regimen (P < 0.001).
There were no statistically significant differences in the incidence of adverse events between the biweekly ETN therapy group and the every-other-week ETN therapy group. Baseline characteristics associated with a major clinical response to ETN were shorter disease duration, raised CRP, and a higher BASDAI. However, no statistical significance for any of these parameters was present.
DISCUSSION
There is a lack of consensus on the attitude to adopt in PsA patients, in presence of sustained clinical remission under biological therapy. Some observational studies showed that PsA patients, as well as patients presenting only skin psoriasis, remain in remission, sometimes also for a long period after therapy discontinuation, thus suggesting an intermittent therapeutic strategy. [8] [9] [10] [17] [18] [19] Despite 2 studies, limited and poorly controlled, which have shown that intermittent treatment induces a rapid efficacy even after reinduction, 20, 21 further trials have suggested that complete withdrawal of treatment leads to relapse in most patients, and most cases, a delay has been observed in achieving again remission during retreatment. [20] [21] [22] Similarly, some studies with ETN reported a Etanercept to Maintain Remission in PsA significantly higher proportion of patients attaining PASI-75 with continuous, rather than with intermittent, "as needed" therapy. 23, 24 On the contrary, a progressive increase in the dosing interval along with disease activity monitoring has been implemented empirically in recent years in the rheumatology practice. Furthermore, the Spanish Society of Rheumatology, in the consensus document on the use of biological therapies in PsA, assumes that there is no current evidence to recommend biological reduction in this disease, which can, however, be considered individually. 25 The effectiveness of such strategy has been, at least in part, certified by some observational studies suggesting the possibility of reducing the dose of biological agents in these patients to the lowest efficient dose without having an increase in disease activity. [11] [12] [13] [14] [15] On the other hand, there are virtually no studies designed to determine the effectiveness of dose reduction strategies, and such practice remains clinically empirical.
The results of our study seem to reinforce this approach. In fact, it indicates that a consistent percentage (72%) of subjects with PsA, achieving a sustained remission with ETN 25 mg biweekly, maintains a remission after a year of starting therapy, despite a progressive increase in the dosing interval: 21% with a weekly regimen and 51% with an every-other-week regimen. The patients who, by increasing the dosing intervals, showed reactivation of the disease reached again, usually within 1 month, a new remission, comparable to that obtained initially, by means of restoration of previously efficient treatment schedule.
Our results show significantly that the main reasons that hinder the dosing interval increase of ETN in PsA patients in sustained clinical remission at standard doses are peripheral polyarthritis pattern and exacerbation of cutaneous manifestations. None of the patients presenting axial pattern or oligoarthritis showed an increased disease activity when switching to a weekly regimen. Only 18% (2/11) of peripheral oligoarthritis patients and 14% (1/7) of axial pattern patients showed an increased disease activity when switching to an every-other-week regimen in sustaining clinical remission with ETN 25 mg weekly. On the contrary, 50% (4/8) of peripheral polyarthritis patients in sustained clinical remission showed an exacerbation of arthritic manifestations with ETN dose interval increase.
The efficacy of ETN is greater on arthritic manifestations than on the skin disease, and in fact, after few weeks from the interval increase to weekly regimen, 45% of patients showed an increase in PASI, and only 69% (11 patients) of them continued PASI-75. Similarly, with ETN interval increase to every-other-week regimen, only 43% (7 patients) of patients kept showing a PASI-75. In approximately 17% of cases (5 patients), we had to return to standard dose of ETN because of a significant worsening of the skin psoriatic manifestations. In the majority of those patients, returning to the dose previously efficient allowed to quickly return to a significant increase in PASI. Our data on the different efficacy of anti-tumor necrosis factor α on skin manifestations and on arthritis manifestations are similar to those indicated from controlled study. 26 Etanercept dosage reduction is not associated with a reduction in adverse events, but it is likely that reliable conclusions with regard to risk reduction of adverse events can only come from comparative studies of longer duration.
The major limitations of our study are the open-label design, small sample, unusual pattern of musculoskeletal involvement, absence of randomization and of blinded arm, and the new definition of remission. The patients in our study were selected because they were refractory to conventional DMARDs, usually more effective in oligoarthritis patients; this can justify the high percentage of patients with peripheral polyarthritis and axial pattern compared with those showing peripheral oligoarthritis. We considered 2 different measures of effectiveness, because of the different efficacy of ETN on articulary manifestations and cutaneous ones: while psoriasis severity was assessed based on the PASI score, we adopted a new concept of clinical remission for extracutaneous inflammatory manifestations, defined by the absence of actively inflamed joints (peripheral and axial), extraarticular enthesitis manifestations, and all other extra-articular manifestations except the cutaneous ones. In reality, there is no consensus on a definition of remission in PsA. The more common tool used is Minimal Disease Activity that includes the PASI, but it does not exclude minimal peripheral polyarthritis pattern, and it does not consider the axial pattern. 27, 28 Furthermore, sustained remission usually refers to remission for at least 6 months. However, for the characteristics and especially for the duration of our study, we defined sustained remission as fulfillment of the remission criteria at 2 consecutive visits, at least 1 month apart, with complete data sets according Mierau et al. 28 Finally, the short duration of our observational study should be emphasized; it will be necessary to extend the study by using as a measure of outcome the extent of the progression of structural damage defined by a radiographic assessment.
Despite these caveats, our results are reliable enough to suggest that it is possible to increase ETN dose interval in patients with remitting PsA initially treated with standard doses; particularly, it seems possible in patients with axial pattern or peripheral oligoarthritis and moderate cutaneous manifestations. In conclusion, it seems natural that a progressive dose reduction of biological agents should play a crucial role in the therapeutic strategy of PsA. Our results are in favor of the clinical practice commonly used in many rheumatology services and possibly can increase it in the context of the strict control of health resources.
